Alterity Therapeutics Limited (ATHE) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Melbourne, VIC, 澳大利亚. 现任CEO为 David A. Stamler.
ATHE 拥有 IPO日期为 2003-09-29, 10 名全职员工, 在 NASDAQ Capital Marke, 市值为 $32.81M.
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
